Steve Cohen recommended BridgeBio as a top biotech stock on July 25, 2025.
3 reports, 2 independent
Updated Jul 25
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Steve Cohen recommended BridgeBio as a top biotech stock on July 25, 2025.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
BridgeBio
company in Palo Alto, United States
-
Steve Cohen
researcher (ORCID 0000-0002-9471-4586)
Nothing else this week.
Related events
Coverage
Newest first; wire copies grouped- Insider MonkeyTruist Sees Upside in BridgeBio Pharma’s (BBIO) ATTR-CM Strategy BridgeBio Pharma Inc. (NASDAQ:BBIO) is one of the best biotech stocks to buy according to billionaire Steve Cohen. On July 21, Truist
- Insider MonkeyMorgan Stanley Upgrades Amicus (FOLD) on IP Strength and Pipeline Expansion Amicus Therapeutics, Inc. (NASDAQ:FOLD) is one of the best biotech stocks to buy according to billionaire Steve Cohen. On J
- GlobeNewswireNovel Human Genetics Evidence Confirms Estimates of Genetic Prevalence, Underdiagnosis, and Potentially Greater Symptom Burden of Gain-of-Function CASR Variants Associated with ADH1 - By examining ov